Marleen I. Meyers

Biosketch / Results /

Marleen I. Meyers, M.D.

Assistant Professor;
Department of Medicine (Residency Program)
NYU Medical Oncology Associates

Clinical Addresses

160 EAST 34 STREET, 2 FLOOR
NEW YORK, NY 10016
Hours: Mon. 10 - 5; Wed. 10 - 5; Fri. 10 - 1
Handicap Access: yes
Phone: 212-731-5348
Fax: 212-731-5574

« Back to Results

Medical Specialties

Cancer, Medical Oncology

Medical Expertise

Breast Cancer, Breast Oncology

Insurance

AETNA HMO, AETNA INDEMNITY, AETNA MEDICARE, AETNA POS, AETNA PPO/EPO, AFFINITY, AFFINITY EXCHANGE- ESSENTIAL, CIGNA EPO/POS, Cigna PPO, EBCBS EPO, EBCBS HLTHY NY, EBCBS HMO, EBCBS INDEMNITY, EBCBS MEDIBLUE, EBCBS POS, EBCBS PPO, GHI CBP, METROPLUS CHLD HLTH, METROPLUS EXCHANGE PLANS, METROPLUS FAM HLTH, MULTIPLAN/PHCS PPO, Medicare, NYS EMPIRE PLAN, OXFORD EXCHANGE, OXFORD FREEDOM, Oxford Liberty, Oxford Medicare, UHC COMMUNITY & STATE PLAN, UHC EPO, UHC HMO, UHC MEDICARE, UHC POS, UHC PPO, UHC TOP TIER, UNITED EXCHANGE- COMPASS, UPN Elite, WELLCARE CHLD HLTH, WELLCARE FAM HLTH, WELLCARE MEDICAID

Insurance Disclaimer: Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have changed.

« Back to Results

Board Certification

1982 — Ab Internal Medicine - Internal Medicine
1985 — Ab Internal Medicine (Medical Oncology)

Education

1975-1979 — New York University School of Medicine, Medical Education
1979-1980 — NYU Medical Center (Medicine), Internship
1980-1983 — NYU Medical Center (Medicine), Residency Training
1983-1985 — Memorial Hospital for Cancer & Allied Diseases (Oncology), Clinical Fellowships

« Back to Results

Research Interests

Pharmacokinetics of the Cardioprotector ADR-529.

« Back to Results

All data from NYU Health Sciences Library Faculty Bibliography — -

Contact:
http://hsl.med.nyu.edu/faculty-bibliography-search

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
Singh, JC; Novik, Y; Stein, S; Volm, M; Meyers, M; Smith, J; Omene, C; Speyer, J; Schneider, R; Jhaveri, K; Formenti, S; Kyriakou, V; Joseph, B; Goldberg, JD; Li, X; Adams, S; Tiersten, A
2014 ;16(2):- R32, Breast cancer research
— id: 1059672, year: 2014, vol: 16, page: , stat: Journal Article,

RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial
Singh, J C; Stein, S; Volm, M; Smith, J A; Adams, S; Meyers, M; Speyer, J L; Novik, Y; Schneider, R; Formenti, S; Muggia, F; Jhaveri, K L; Goldberg, J D; Heese, S; Li, X; Davis, S; Tiersten, A
2013 20 May 2013;31(15):-, Journal of clinical oncology
— id: 452012, year: 2013, vol: 31, page: , stat: Journal Article,

Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer
Singh, J C; Stein, S; Volm, M; Smith, J A; Novik, Y; Speyer, J L; Meyers, M; Adams, S; Omene, C O; Muggia, F; Schneider, R; Formenti, S; Davis, S; Beardslee, B; Tiersten, A
2012 20 May 2012;30(15):-, Journal of clinical oncology
— id: 249952, year: 2012, vol: 30, page: , stat: Journal Article,

Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study
Singh, J C; Volm, M; Novik, Y; Speyer, J L; Adams, S; Omene, C O; Meyers, M I; Smith, J A; Schneider, R; Formenti, S; Goldberg, J D; Li, X; Davis, S; Beardslee, B; Tiersten, A
2012 20 Sep 2012;30(27):-, Journal of clinical oncology
— id: 395172, year: 2012, vol: 30, page: , stat: Journal Article,

Vinorelbine/cisplatin therapy of locally advanced and metastatic breast cancer: an active regimen
Hochster H; Wasserheit C; Siddiqui N; Sorich J; Downey A; Wernz J; Oratz R; Meyers M; Moskovits T; Speyer J
1997 ;16:A606-A606, Proceedings (American Society of Clinical Oncology)
— id: 6028, year: 1997, vol: 16, page: A606, stat: Journal Article,

Phase II trial of paclitaxel and cisplatin (DDP) in women with metastatic breast cancer
Wasserheit C; Alter R; Speyer J; Hochster H; Oratz R; Wernz J; Chachoua A; Meyers M; Sorich J; Downey A; et al
1994 ;13:A204-A204, Proceedings (American Society of Clinical Oncology)
— id: 6017, year: 1994, vol: 13, page: A204, stat: Journal Article,

Topotecan 21-day continuous infusion: excellent tolerance of a novel schedule
Hochster H; Speyer J; Oratz R; Meyers M; Wemz J; Chachoua A; Raphael B; Lee R; Sorich J; Taubes B; et al
1993 ;12:A356-A356, Proceedings (American Society of Clinical Oncology)
— id: 6015, year: 1993, vol: 12, page: A356, stat: Journal Article,

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin
Hochster H; Liebes L; Wadler S; Oratz R; Wernz JC; Meyers M; Green M; Blum RH; Speyer JL
1992 Nov 18;84(22):1725-1730, Journal of the National Cancer Institute
— id: 57431, year: 1992, vol: 84, page: 1725, stat: Journal Article,

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer [published erratum appears in J Clin Oncol 1992 May;10(5):867]
Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M; et al
1992 Jan;10(1):117-127, Journal of clinical oncology
— id: 13730, year: 1992, vol: 10, page: 117, stat: Journal Article,

Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial
Oratz R; Speyer JL; Wernz JC; Hochster H; Meyers M; Mischak R; Spitler LE
1990 Aug;9(4):345-354, Journal of biological response modifiers
— id: 15689, year: 1990, vol: 9, page: 345, stat: Journal Article,

A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer
Speyer JL; Green MD; Sanger J; Zeleniuch-Jacquotte A; Kramer E; Rey M; Wernz JC; Blum RH; Hochester H; Meyers M; et al
1990 Sep;17(2-3):161-163, Cancer treatment reviews
— id: 15688, year: 1990, vol: 17, page: 161, stat: Journal Article,

Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients
Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M; et al
1989 ;23(5):323-328, Cancer chemotherapy & pharmacology
— id: 10796, year: 1989, vol: 23, page: 323, stat: Journal Article,

Phase I study of the combination of alpha-2 interferon and cisplatinum
Walsh C; Speyer JL; Wernz J; Hochster H; Grossberg H; Chachoua A; Molinaro P; Meyers M; Blum RH
1989 Feb;8(1):11-15, Journal of biological response modifiers
— id: 10721, year: 1989, vol: 8, page: 11, stat: Journal Article,

PHASE-I STUDY OF THE COMBINATION OF ALFA-2 INTERFERON AND CISPLATINUM
Walsh, CM; Speyer, JL; Wernz, JC; Meyers, MI; Widman, T; Grossberg, HS; Spiegel, RJ; Blum, RH
1987 Mar;28(3):231-231, Proceedings (American Association for Cancer Research)
— id: 31225, year: 1987, vol: 28, page: 231, stat: Journal Article,